<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355612</url>
  </required_header>
  <id_info>
    <org_study_id>RESAPAS Trial</org_study_id>
    <nct_id>NCT03355612</nct_id>
  </id_info>
  <brief_title>XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma</brief_title>
  <official_title>A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multicenter, controlled study to compared the Efficacy and Safety of&#xD;
      XELOX combined with Apatinib versus XELOX as post-operative chemotherapy in locally advanced&#xD;
      gastric signet ring carcinoma with D2 dissection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to prove that as for disease free survival time, and safety,&#xD;
      Apatinib with XELOX(Oxaliplatin with Capecitabine) has a better effect over that of XELOX&#xD;
      adjunct therapy group for postoperative chemotherapy of locally advanced gastric signet ring&#xD;
      carcinoma with D2 dissection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival(DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Disease Free Survivalof the Participants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>8 years</time_frame>
    <description>Overall Survival of the Participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of Participants With Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Gastric Carcinoma</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:Apatinib with XELOX(Capecitabine and Oxaliplatin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>active comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug:XELOX(Capecitabine and Oxaliplatin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib: 500 mg, qd, po, last 180 days</description>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>YN968D1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w</description>
    <arm_group_label>active comparator</arm_group_label>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>Capecitabine and Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. ≥ 18 and ≤ 70 years of age;&#xD;
&#xD;
          -  2. Eastern Cooperative Oncology Group Performance Status: 0-1;&#xD;
&#xD;
          -  3. Had been treated with Radical resection (D2, R0) of gastric cancer (Lymph node≥16);&#xD;
&#xD;
          -  4. Postoperative histological proven gastric signet-ring cell carcinoma(or contains&#xD;
             signet-ring cell carcinoma);&#xD;
&#xD;
          -  5. Pathological stage:IIIA-IIIC（8th AJCC TNM）;&#xD;
&#xD;
          -  6. Patients have adequate baseline organ and marrow function :hemoglobin≥9g/dL;&#xD;
             absolute neutrophil count (ANC) ≥1,500/mm3; PLT(platelets)≥1000,000/mm3; total&#xD;
             bilirubin ≤1.5×upper normal limit(ULN); AST ≤2.5 ×ULN, ALT ≤2.5 ×ULN; prothrombin&#xD;
             time-international normalized ratio≤1.5, and APTT(activated partial thromboplastin&#xD;
             time) was within normal range; creatine ≤ 1.5 x ULN;&#xD;
&#xD;
          -  7. The ECG(electrocardiography) was basically normal in the 4 weeks before the study,&#xD;
             and there was no obvious clinical symptoms of heart disease;&#xD;
&#xD;
          -  8. sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients with hypertension and uncontrolled hypertension with hypotensive drugs&#xD;
             therapy ;&#xD;
&#xD;
          -  2. Patients with dysphagia, complete or incomplete digestive tract obstruction,&#xD;
             gastrointestinal bleeding, perforation, etc;&#xD;
&#xD;
          -  3. Patients had bradycardia or a QT extension;&#xD;
&#xD;
          -  4. Patients had gastrointestinal fistula and lacerations after surgery;&#xD;
&#xD;
          -  5. Allergic to capecitabine or oxaliplatin, or metabolic disorders;&#xD;
&#xD;
          -  6. Patients accepted Preoperative chemotherapy, radiotherapy or targeted therapy;&#xD;
&#xD;
          -  7. Attending other drug clinical trials;&#xD;
&#xD;
          -  8. Patients with Serious liver disease (such as cirrhosis, etc.), kidney disease,&#xD;
             respiratory disease or uncontrolled diabetes, hypertension and other chronic systemic&#xD;
             diseases, heart disease with Clinical symptoms（such as congestive heart failure,&#xD;
             coronary heart disease symptoms, drug is difficult to control arrhythmia,&#xD;
             hypertension, or six months had a myocardial infarction attack, or cardiac&#xD;
             insufficiency）;&#xD;
&#xD;
          -  9. Patients with peripheral nervous system disorder or apparent mental disorders or&#xD;
             had the history of central nervous system disorders;&#xD;
&#xD;
          -  10. Patients with serious infection(above CTCAE grade 2);&#xD;
&#xD;
          -  11. Patient with history of another malignant cancer within past 5 years（not&#xD;
             including: cervical carcinoma in situ, non melanoma skin cancer and superficial&#xD;
             bladder tumor );&#xD;
&#xD;
          -  12. Have the history of organ transplantation, Or have received systemic steroid&#xD;
             therapy for a long time (note: short term user stopping medication &gt;2 weeks can be&#xD;
             included);&#xD;
&#xD;
          -  13. Pregnant or lactating women, women of child-bearing potential, unwilling to use&#xD;
             adequate contraceptive protection during the process of the study;&#xD;
&#xD;
          -  14. Patients without legal capacity,or medical/ethical reasons may influence the study&#xD;
             to continue.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Han Liang, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Han Liang, Master</last_name>
    <phone>（022）23340123</phone>
    <phone_ext>1063</phone_ext>
    <email>tjlianghan@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingzhi Cai, Master</last_name>
    <phone>13821389052</phone>
    <email>tsaimingzhi@163.com</email>
  </overall_contact_backup>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>November 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>November 22, 2017</last_update_submitted>
  <last_update_submitted_qc>November 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Signet Ring Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

